These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 11877472

  • 1. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
    Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, Racke MK.
    J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
    Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ.
    J Immunol; 2006 Jun 01; 176(11):7119-29. PubMed ID: 16709875
    [Abstract] [Full Text] [Related]

  • 3. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
    Putheti P, Soderstrom M, Link H, Huang YM.
    J Neuroimmunol; 2003 Nov 01; 144(1-2):125-31. PubMed ID: 14597106
    [Abstract] [Full Text] [Related]

  • 4. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.
    Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ.
    J Neuroimmunol; 2006 Nov 01; 180(1-2):159-71. PubMed ID: 16935352
    [Abstract] [Full Text] [Related]

  • 5. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
    Arbour N, Rastikerdar E, McCrea E, Lapierre Y, Dörr J, Bar-Or A, Antel JP.
    Mult Scler; 2005 Dec 01; 11(6):652-7. PubMed ID: 16320724
    [Abstract] [Full Text] [Related]

  • 6. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
    Blanco Y, Moral EA, Costa M, Gómez-Choco M, Torres-Peraza JF, Alonso-Magdalena L, Alberch J, Jaraquemada D, Arbizu T, Graus F, Saiz A.
    Neurosci Lett; 2006 Oct 09; 406(3):270-5. PubMed ID: 16934924
    [Abstract] [Full Text] [Related]

  • 7. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate.
    Ratts RB, Lovett-Racke AE, Choy J, Northrop SC, Hussain RZ, Karandikar NJ, Racke MK.
    J Neuroimmunol; 2006 Sep 09; 178(1-2):117-29. PubMed ID: 16837065
    [Abstract] [Full Text] [Related]

  • 8. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
    Berthelot L, Miqueu P, Pettré S, Guillet M, Moynard J, Wiertlewski S, Lefrère F, Brouard S, Soulillou JP, Laplaud DA.
    Clin Immunol; 2010 Apr 09; 135(1):33-42. PubMed ID: 20116333
    [Abstract] [Full Text] [Related]

  • 9. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S, Abramczyk S, Lisak D, Lisak R.
    Mult Scler; 2001 Feb 09; 7(1):43-7. PubMed ID: 11321193
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
    Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS.
    Mult Scler; 2013 Feb 09; 19(2):179-87. PubMed ID: 22653658
    [Abstract] [Full Text] [Related]

  • 11. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
    Dressel A, Vogelgesang A, Brinkmeier H, Mäder M, Weber F.
    J Neuroimmunol; 2006 Dec 09; 181(1-2):133-40. PubMed ID: 17084909
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA.
    J Clin Invest; 2000 Apr 09; 105(7):967-76. PubMed ID: 10749576
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.
    Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, Zamvil SS, Gougeon ML, Chofflon M, Lalive PH.
    J Neuroimmunol; 2007 Apr 09; 185(1-2):123-9. PubMed ID: 17306890
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
    Zafranskaya M, Oschmann P, Engel R, Weishaupt A, van Noort JM, Jomaa H, Eberl M.
    Immunology; 2007 May 09; 121(1):29-39. PubMed ID: 17239199
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.